Navigation Links
ANI Pharmaceuticals, Inc. Announces Date for Third Quarter 2013 Earnings Release
Date:10/29/2013

BAUDETTE, Minn., Oct. 29, 2013 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will release its third quarter 2013 earnings before the market opens on Thursday, November 7th, 2013.

About ANI

ANI is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. In two facilities with combined manufacturing, packaging and laboratory capacity totaling 173,000 square feet, ANI manufactures oral solid dose products, as well as liquids and topicals, including narcotics and those that must be manufactured in a fully contained environment due to their potency and/or toxicity. ANI also performs contract manufacturing for other pharmaceutical companies. Over the last two years ANI has launched three new products and has twelve products in development. ANI's targeted areas of product development include narcotics, anti-cancers and hormones (potent compounds), and extended release niche generic product opportunities. ANI's other products include an FDA-approved testosterone gel, which is licensed to Teva Pharmaceuticals USA. For more information please visit our website www.anipharmaceuticals.com.

Forward-Looking Statements

To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the potential benefits of the merger, the combined company's plans, objectives, expectations and intentions with respect to future operations and products, the anticipated financial position, operating results and growth prospects of the combined company and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "plans," "potential," "future," "believes," "intends," "continue," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause the combined company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include the risk that the Company may in the future be required to seek FDA approval for its unapproved products or withdraw such products from the market; the Company may fail to meet NASDAQ listing requirements; general business and economic conditions; the Company's need for and ability to obtain additional financing; the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; and the marketing success of the Company's licensees or sublicensees. More detailed information on these and additional factors that could affect the Company's actual results are described in the Company's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and this quarterly report on Form 10-Q, as well as its proxy statement/prospectus, filed with the Securities and Exchange Commission on May 8, 2013. All forward-looking statements in this quarterly report speak only as of the date made and are based on the Company's current beliefs and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information about ANI, please contact:
Arthur S. Przybyl
(218) 634-3608
arthur.przybyl@anipharmaceuticals.com


'/>"/>
SOURCE ANI Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals, Inc. States that its Policy is Not to Comment on Unusual Market Activity
2. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Cellulite Study of Collegenase Clostridium Histolyticum
3. Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial
4. Ampio Pharmaceuticals, Inc. Announces $25 Million Financing
5. KaloBios Pharmaceuticals, Inc. Prices Public Offering of Common Stock
6. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. -- AMAG
7. Boehringer Ingelheim Pharmaceuticals, Inc. colabora con Univision Communications Inc. para lanzar una campaña integrada en español
8. Boehringer Ingelheim Pharmaceuticals, Inc. Collaborates With Univision Communications Inc. To Launch An Integrated Campaign In Spanish
9. Harwood Feffer LLP Announces Investigation of Transcept Pharmaceuticals, Inc.
10. Auxilium Pharmaceuticals, Inc. Raises $50 Million In Additional Financing
11. Rafarma Pharmaceuticals, Inc. (RAFA) announces plans for PCAOB-Registrant Audit and Streamlining of Corporate Structure to Upgrade Market Listing.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Jan. 16, 2017  Today, Analytics 4 Life (A4L), ... announced its expansion into JLABS @ Toronto ... science incubators. As a resident in the space, A4L ... device development and commercialization expertise. JLABS @ ... innovation center that provides a flexible environment for start-up ...
(Date:1/15/2017)... , January 16, 2017 Le conseil ... à base de collagène pour la régénération de tissus humains, ... poste de directeur général avec effet immédiat. ... Bill est un dirigeant ... occupé plusieurs postes de gestion générale et de direction au ...
(Date:1/13/2017)... Stock-Callers is currently reviewing the following Medical Appliances ... WMGI ), Varian Medical Systems Inc. (NYSE: VAR ... NuVasive Inc. (NASDAQ: NUVA ). These companies belong ... finish on Thursday, January 12 th , 2017, with the ... health care companies in the S&P 500 were down less ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Houston dentist, Dr. Behzad ... offering complimentary consultations and financing for orthodontics for a limited time. Complimentary for ... learn about their orthodontic options. Walk-in, late-evening, Saturday, and same-day appointments are available. ...
(Date:1/16/2017)... ... ... well-aware of the following facts at present:, Flu and cold ... effect on keeping this particularly bad strain of the flu away , In ... , These facts are well-known among the team at Woodard! About halfway ...
(Date:1/16/2017)... ... January 16, 2017 , ... San Francisco dentist, Dr. Ben ... in 3-D scanning device which is capable of taking digital impressions of teeth and ... such as CAD CAM restorations , in terms of speed, efficiency and patient ...
(Date:1/15/2017)... ... ... is announcing the release of an updated version of their top selling clipper, the ... wide jaws that will accommodate nails up to 4mm in thickness . Nails like ... reinforced for extra strength when pressing down on dense nails which can be a hindrance ...
(Date:1/15/2017)... , ... January 15, 2017 , ... The Gravity Vault ... in Radnor, Pennsylvania. As construction wraps up on the 14,000+ square foot climbing gym, ... Vaults sixth location, including three in New Jersey and two in New York. With ...
Breaking Medicine News(10 mins):